Externally-Funded Research Fellow (B)
School of Biomedicine
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Adikusuma is a research scientist in the Genome Editing Laboratory led by Prof Paul Thomas at the University of Adelaide and the South Australian Health and Medical Research Institute (SAHMRI). He completed his PhD at the University of Adelaide under Prof Thomas supervision. He is an ARC DECRA fellow (2023-2025) and was previously a fellow of CSIRO Synthetic Biology Future Science Platform (2018-2021). Dr Adikusuma's research focuses on developing CRISPR gene editing techniques and strategies to improve the efficiency of the intended gene editing outcomes. He discovered the strategies to eliminate an entire chromosome using CRISPR genome editing. Also, his landmark finding that CRISPR-Cas9 cleavage often induces large deletions (Adikusuma et al Nature 2018) cautions the biomedical community about unintended and hitherto unrecognised editing outcomes that could occur when performing germline CRISPR genome editing therapy. His research is also focused on developing highly efficient CRISPR gene editing techniques for the therapeutic of genetic diseases such as Duchenne Muscular Dystrophy, Retinitis Pigmentosa, and Cystic Fibrosis. He received numerous awards including the Early Career Researcher Award from the Faculty of Health and Medical Science University of Adelaide (2022), and the Early Career Researcher Award from SAHMRI (twice in 2018 and 2022). He was also a finalist for the University of Adelaide ECR award.
My research is focused on developing CRISPR genome editing technology particularly for its use in mammalian cells and in mice. I explore CRISPR strategies that promote predictable and efficient DNA editing outcomes. For example, I invented the strategies to eliminate an entire chromosome using CRISPR genome editing (Adikusuma et al Molecular Therapy 2017). I also discovered an easy way to generate precise gene-edited mouse embryos using the Nuclease Prime Editor. My research also studies how we can efficiently and effectively create genomic mutations using CRISPR technology and develop the CRISPR tools (constructs) to achieve the goal. Additionally, I study the repair outcomes (mutations) generated after DNA breaks induced by CRISPR endonuclease. For example, we found that CRISPR-Cas9 cleavage often induces large deletions (Adikusuma et al Nature 2018). The main goal of my research is to create knowledge and technology on genome editing that is widely used for vast applications such as basic research and therapeutics. My research projects also focus on developing highly effective CRISPR therapy for genetic diseases such as Duchenne Muscular Dystrophy (DMD), Retinitis Pigmentosa, and Cystic Fibrosis. We use mammalian cells and animal preclinical models to test our CRISPR techniques in order to find the perfect formula that can effectively cure genetic diseases. Ultimately, the research is expected to develop CRISPR therapies for use in humans to provide treatments for patients.
Date Position Institution name 2018 - ongoing Research Fellow University of Adelaide, Adelaide 2017 - 2018 Postdoctoral Researcher University of Adelaide, Adelaide
Awards and Achievements
Date Type Title Institution Name Country Amount 2023 Award ARC DECRA 2023 (Discovery Early Career Research Award) Australian Research Council (ARC) Australia - 2022 Award SAHMRI 2022 Early Career Researcher Award South Australian Health and Medical Research Institute Australia - 2022 Award 2022 Faculty Emerging Leader Development Award University of Adelaide, Faculty of Health and Medical Sciences Australia - 2022 Award Early Career Researcher Executive Dean Award (2022) Faculty of Health and Medical Science Australia - 2021 Award Faculty Emerging Leader Development Award Faculty of Health and Medical Science, University of Adelaide Australia - 2018 Award Early Career Researcher Award SAHMRI Australia - 2018 Fellowship CSIRO SynBio Fellowship CSIRO, University of Adelaide and SAHMRI Australia -
Date Institution name Country Title University of Adelaide, Adelaide Australia PhD (awarded in Jan 2018)
Year Citation 2023 Chey, Y. C. J., Arudkumar, J., Aartsma‐Rus, A., Adikusuma, F., & Thomas, P. Q. (2023). CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies. WIREs Mechanisms of Disease, 15(1), e1580-1-e1580-26.
DOI Scopus5 WoS4 Europe PMC4
2022 Burbano, L. E., Li, M., Jancovski, N., Jafar-Nejad, P., Richards, K., Sedo, A., . . . Petrou, S. (2022). Antisense oligonucleotide therapy for KCNT1 encephalopathy. JCI insight, 7(23), 1-20.
DOI Scopus5 WoS5 Europe PMC1
2021 Adikusuma, F., Lushington, C., Arudkumar, J., Godahewa, G. I., Chey, Y. C. J., Gierus, L., . . . Thomas, P. Q. (2021). Optimized nickase- and nuclease-based prime editing in human and mouse cells. Nucleic Acids Research, 49(18), 10785-10795.
DOI Scopus27 WoS26 Europe PMC18
2021 Thomson, E., Dawson, R., H'ng, C. H., Adikusuma, F., Piltz, S., & Thomas, P. Q. (2021). The Nestin neural enhancer is essential for normal levels of endogenous Nestin in neuroprogenitors but is not required for embryo development. PLoS One, 16(11), e0258538-1-e0258538-16.
DOI Scopus1 WoS1 Europe PMC1
2020 Pfitzner, C., White, M. A., Piltz, S. G., Scherer, M., Adikusuma, F., Hughes, J. N., & Thomas, P. Q. (2020). Progress Toward Zygotic and Germline Gene Drives in Mice.. CRISPR J, 3(5), 388-397.
DOI Scopus16 WoS14 Europe PMC15
2019 Prowse, T. A., Adikusuma, F., Cassey, P., Thomas, P., & Ross, J. V. (2019). A Y-chromosome shredding gene drive for controlling pest vertebrate populations. eLife, 8, e41873-1-e41873-19.
DOI Scopus27 WoS23 Europe PMC15
2018 Robertson, L., Pederick, D., Piltz, S., White, M., Nieto, A., Ahladas, M., . . . Thomas, P. Q. (2018). Expanding the RNA-Guided Endonuclease Toolkit for Mouse Genome Editing.. The CRISPR journal, 1(6), 431-439.
DOI WoS4 Europe PMC3
2018 Adikusuma, F., Piltz, S., Corbett, M. A., Turvey, M., McColl, S. R., Helbig, K. J., . . . Thomas, P. Q. (2018). Large deletions induced by Cas9 cleavage. Nature, 560(7717), E8-E9.
DOI Scopus188 WoS180 Europe PMC137
2017 Adikusuma, F., Pederick, D., McAninch, D., Hughes, J., & Thomas, P. (2017). Functional equivalence of the SOX2 and SOX3 transcription factors in the developing mouse brain and testes. Genetics, 206(3), 1495-1503.
DOI Scopus15 WoS16 Europe PMC11
2017 Adikusuma, F., Williams, N., Grutzner, F., Hughes, J., & Thomas, P. (2017). Targeted Deletion of an Entire Chromosome Using CRISPR/Cas9. Molecular Therapy, 25(8), 1736-1738.
DOI Scopus55 WoS58 Europe PMC39
2017 Van Der Hoek, K., Eyre, N., Shue, B., Khantisitthiporn, O., Glab-Ampi, K., Carr, J., . . . Beard, M. (2017). Viperin is an important host restriction factor in control of Zika virus infection. Scientific Reports, 7(1), 4475 -1-4475-14.
DOI Scopus83 WoS82 Europe PMC62
2017 Adikusuma, F., Pfitzner, C., & Thomas, P. (2017). Versatile single-step-assembly CRISPR/Cas9 vectors for dual gRNA expression. PloS one, 12(12), 1-11.
DOI Scopus25 WoS21 Europe PMC21
2014 Piltz, S., Adikusuma, F., Hughes, J., & Thomas, P. (2014). Rapid generation of mutant mice using CRISPR-mediated genome editing (tips and tricks). TRANSGENIC RESEARCH, 23(5), 867. - Adikusuma, F., Lushington, C., Arudkumar, J., Godahewa, G. I., Chey, Y. C. J., Gierus, L., . . . Thomas, P. Q. (n.d.). Optimized nickase- and nuclease-based prime editing in human and mouse cells.
Year Citation 2020 Pfitzner, C., Prowse, T., Adikusuma, F., Piltz, S., Cassey, P., Ross, J., & Thomas, P. (2020). Safe development of CRISPR gene drives for invasive rodent population suppression. Poster session presented at the meeting of TRANSGENIC RESEARCH. SPRINGER. 2014 Piltz, S. G. (2014). Rapid generation of mutant mice using CRISPR mediated genome editing (tips and tricks). Poster session presented at the meeting of Transgenic Research. Ediburgh, UK: Springer.
- Australian Research Council (ARC) Discovery Early Researcher Career Award (DECRA, 2023-2025): $458,238
- CSIRO Synthetic Biology Future Science Platform Fellowship (2018-2021): $489,768
- 2022 University of Adelaide, Faculty of Health & Medical Science Emerging Leaders Development (FHMS ELD) Award ($38,974).
- 2021 University of Adelaide, Faculty of Health & Medical Science Emerging Leaders Development (FHMS ELD) Award ($39,800).
- Advanced Research Platforms, Masters of Biotechnology
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2023 Principal Supervisor Investigating Prime Editing Strategies to correct Large Duplications causing Duchenne's Muscular Dystrophy in primary myoblast and humanised mice models Master of Philosophy (Medical Science) Master Full Time Mr Ryan Hao Bing Lee 2022 Co-Supervisor The Development of Novel CRISPR/Cas9 Based Therapies for Genetic Eye Disease Master of Philosophy (Medical Science) Master Full Time Miss Jesse Georgina Kennedy 2022 Co-Supervisor Designing a novel therapeutic CRISPR/Cas9 based strategy towards treating genetic eye disease Master of Philosophy (Medical Science) Master Full Time Mr Lachlan Graham Staker 2021 Co-Supervisor Improving Disease Therapy with the Application of Prime Editing Doctor of Philosophy Doctorate Full Time Mr Caleb James Lushington 2021 Co-Supervisor Development of novel CRISPR/Cas9 therapies for genetic eye disease Doctor of Philosophy Doctorate Full Time Ms Ashleigh Geiger 2020 Co-Supervisor Developing CRISPR/Cas9-Based Therapy for Duchenne Muscular Dystrophy using a Humanised Preclinical Model Doctor of Philosophy Doctorate Full Time Mr Yu Chinn Joshua Chey 2020 Co-Supervisor Development of a highly efficient CRISPR-Cas9 gene therapy strategy for precise restoration of dystrophin in Duchenne Muscular Dystrophy (DMD) Doctor of Philosophy Doctorate Full Time Mr Jayshen Christa Arudkumar
Connect With Me